Senores Pharmaceuticals Limited (NSE:SENORES)

India · Delayed Price · Currency is INR

1,382.90

+3.00 (0.22%)

Sep 23, 2026, 3:29 PM IST

Market Cap	63.71B +95.8%
Revenue (ttm)	6.80B +51.5%
Net Income	1.27B +88.5%
EPS	28.30 +63.9%
Shares Out	46.05M
PE Ratio	48.89
Forward PE	36.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	134,884
Open	1,377.10
Previous Close	1,379.90
Day's Range	1,377.00 - 1,417.90
52-Week Range	662.45 - 1,599.00
Beta	n/a
Analysts	Strong Buy
Price Target	1,620.00 (+17.15%)
Est. Earnings	Nov 6, 2026

About Senores Pharmaceuticals

Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, nutritional ... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 2017

Employees 368

Stock Exchange National Stock Exchange of India

Ticker Symbol SENORES

Full Company Profile

Financial Performance

In fiscal year 2026, Senores Pharmaceuticals's revenue was 6.33 billion, an increase of 58.85% compared to the previous year's 3.98 billion. Earnings were 1.15 billion, an increase of 97.03%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for SENORES stock is "Strong Buy." The 12-month stock price target is ₹1,620, which is an increase of 17.15% from the latest price.

Price Target

₹1,620

(17.15% upside)

Analyst Consensus: Strong Buy

Stock Forecasts